ClinicalTrials.gg
Active, not recruitingNCT05201287Updated Apr 29, 2024

VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

An interventional study of VIA Disc NP in Degenerative Disc Disease, Low Back Pain and Disc Degeneration, sponsored by VIVEX Biologics, Inc.. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by VIVEX Biologics, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
83rd of 141
35 · median 57
Started
2021
with 13 others
No phase
90 of 232
15 open now
Primary completion
2023-01
later than 0 of 57 live
Registered
186th of 232
by date

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 83rd largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2021, is one of 90 with no phase, reaches primary completion later than 0 of the 57 other live ones, and was the 186th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

VIA Disc NP is an allograft intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

Read the detailed description

The study will include adult subjects, ages 18 years or older, with symptomatic lumbar intervertebral disc degeneration that is not adequately resolved by non-surgical standard care. For the purpose of the primary analysis, subjects are considered enrolled in the study once they have signed the informed consent.

Each subject will receive one injection per level (max of 2 levels) and be evaluated for efficacy and safety during the up to 24 month observation period. The study is expected to be completed within 26 months, inclusive of enrollment and follow-up for all subjects.

Subjects will be evaluated at baseline and followed through up to 24 months to establish safety and efficacy of the treatment. The expected duration of subject participation from screening/enrollment through final follow-up is 104 weeks.

03

Conditions studied

  • Degenerative Disc Disease
  • Low Back Pain
  • Disc Degeneration

Keywords

  • low back pain
  • degenerative disc disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility for inclusion is evaluated on a site-specific basis based on each subject's medical, clinical, and radiographic presentation. In addition, for study consistency purposes, the MRI imaging will be submitted to Medical Metrics Imaging (MMI), a core lab, for independent review. MMI will review imaging of every subject to confirm radiographic inclusion criteria. The Medical Monitor will make the final determination for inclusion on all subjects based on review of the MRI relevant medical history and source documents.

  1. Age 18 years or older;
  2. (BMI) \< 35;
  3. Documented diagnosis of moderate radiographic degeneration of up to 2 intervertebral discs from L1 to S1, with a suspected associated discogenic chronic low back pain;
  4. Chronic LBP for ≥ 6 months;
  5. Failed conservative care over the past 3 months of at least 2 conservative treatments including:

    1. oral pain medication [analgesics, and/or non-steroidal anti-inflammatory drugs (NSAIDs)],
    2. structured physical therapy or exercise program prescribed by physical therapist, chiropractor, provider or physician specifically for the treatment of low back pain, and
    3. epidural steroid injections and/or facet injections/selective nerve blocks;
  6. An MRI demonstrating:

    1. 1 to 2 vertebral level involvement L1-S1;
    2. Modified Pfirrmann Grade 3-7;
    3. No modic changes or if changes ≤ 2;
  7. Oswestry Disability Index (ODI) score at time of evaluation of ≥ 40 and ≤ 80 points;
  8. Low back pain of Baseline Numeric Rating Scale (NRS) score of ≥ 6 on the 11-point scale;
  9. No signs or symptoms of current infection;
  10. Be able to give voluntary, written to participate and have signed an Informed Consent Form specific to this study;
  11. Be willing and able to comply with all study procedures and availability for the duration of the study with a of > 2 years.

Exclusion criteria

Exclusion Criteria:

  1. Known allergies to Gentamicin, Vancomycin;
  2. to the proposed sedation/anesthetic protocol;
  3. Radicular pain greater than back pain by history or evidence of radicular pain or neurological deficit within the past 6 months. Radicular pain is defined as nerve pain following a dermatomal distribution and that correlates with nerve compression on imaging. Somatic referred pain is allowed;
  4. Any of the following conditions at the index level:

    1. Contained disc protrusion >5 mm or disc extrusion, or spondylolisthesis >5 mm (lysis and degenerative);
    2. Seronegative spondyloarthropathy;
    3. Symptomatic spinal stenosis (moderate to severe in degree);
    4. Chronic facet syndrome;
    5. Spondylodiscitis;
    6. Bilateral spondylolysis;
    7. Current or history of osteoporotic or tumor-related vertebral body compression fracture;
    8. Previous lumbar spine fusion surgery or disc arthroplasty;
  5. History of sacroiliac (SI) joint pain/injections during the past 3 months or SI joint fusion within the past two years;
  6. Received chemonucleolysis or percutaneous treatment of the affected disc prior to the study;
  7. History of epidural injections within 1 week prior to study treatment;
  8. Received any lumbar intradiscal treatment injection or procedure (e.g., injection of methylene blue, dextrose, glucosamine, and chondroitin sulfate, or biacuplasty) and any nerve ablation procedures at the same or adjacent level (e.g., Basivertebral nerve ablation, dorsal ramus or sinovertebral nerve ablations). Discography and anaesthetic discography may be performed but must be done at least 2 weeks or more prior to the injection procedure;
  9. Been a recipient of prior stem cell/progenitor cell therapy or other biological intervention (e.g., PRP) to repair the target intervertebral disc;
  10. Severe motor deficit or cauda equina disorder based on investigator determination;
  11. Diagnosis of any traumatic neurological disorders;
  12. Severe diseases of any other major body system as judged by the investigator, including malignant diseases of any solid organ or any hematologic during the previous 5 years;
  13. Demonstrate 3 or more Waddell's signs of Inorganic Behavior;
  14. Any mental instability, bipolar disorders, post-traumatic stress disorder (PTSD) or uncontrolled anxiety/depression and/or require new or changed anti-depressants or anti-psychotic medications within 3 months of enrollment;
  15. Compensated injuries or ongoing litigation regarding back pain/injury, or financial or other incentives to remain impaired;
  16. If female and of , are pregnant or breastfeeding or a plan to become pregnant or breastfeed in the first 12 months post-treatment;
  17. Any medical condition that impairs follow-up (i.e., fibromyalgia, rheumatoid arthritis, chronic regional pain syndrome, reflex sympathetic dystrophy);
  18. Evidence of substance abuse (including marijuana); Note: subjects using prescribed extended-release narcotics (e.g., fentanyl patch, MS Contin, oxycontin) within the 3 months prior to screening; subjects on long-acting opioids may be given option to wean off opiates before enrollment. Subjects on short-acting opiates (e.g., hydrocodone, oxycodone, tramadol, etc.) may be included and utilization monitored after the treatment;
  19. Are currently receiving treatment with radiation, chemotherapy, , or chronic steroid therapy (prednisone, or its equivalent, use of up to 5 mg/qd is allowed, as well as inhalation steroids for asthma);
  20. Active implantable devices, such as cardiac pacemakers, spinal cord stimulators, intrathecal pumps, etc.
  21. Bilateral spondylolysis at any level;
  22. Fracture of the spine, previous lumbar spine surgery or previous treatment of the target disc.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    VIA Disc Nucleus Pulposus Allograft

    A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 or 2 levels, L1-S1.

    Other: VIA Disc NP

Interventions

  • OtherVIA Disc NP

    VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.

    Also known as: VIA Disc Nucleus Pulposus Allograft

06

What researchers measure

Primary outcomes

  1. Patient self-reporting of Functional Efficacy with no change in neurological status using the Oswestry Disability Index (ODI)

    Evaluate the change from baseline in functional disability on the Oswestry Disability Index (ODI) measured from 0 (minimal disability) to 100 (maximal disability). The ODI is 10 categories of function to quantify disability due to low back pain.

    Time frame: baseline to 3 months

  2. Review of all Adverse Events for Safety of treatment and product

    Evaluate the incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events from baseline through the final follow-up visit that are related to treatment and product.

    Time frame: baseline to 6 months

Secondary outcomes

  1. Patient self-reporting of Function

    Owestry Disability Index (ODI) is measured 0 (minimal disability) to 100 (maximal disability). This index is comprised of ten categories of function to quantify disability due to low back pain. Functional responder analysis at 3 and 6 months measured as subjects meeting functional improvement of ≥ 10, 15 and 20 points in ODI scores.

    Time frame: 3-6 months

  2. Patient self-reporting of Pain

    Changes in Numeric Rating Scale (NRS) scores. Eleven point pain scale used for patient self-reporting of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable). Analysis at 3 and 6 months measured as subjects meeting lower back pain NRS improvement of 50%.

    Time frame: 3-6 months

  3. Patient self-reporting of Pain in low back

    Changes in Numeric Rating Scale (NRS) scores. Eleven-point pain scale used for patient to self-report level of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable). Analysis at 3 and 6 months measured as subjects meeting lower back pain NRS improvement of ≥30%.

    Time frame: 3-6 months

  4. Oswestry Disability Index (ODI) score change

    Change from baseline in ODI scores at 6 months. Ten category index comprising of function to quantify due to low back pain. ODI is measured 0 (minimal disability) to 100 (maximal disability).

    Time frame: baseline and 6 months

  5. Numeric Rating Scale change

    Changes from baseline in Numeric Rating Scale (NRS) score at 3 and 6 months. Eleven-point pain scale used for patient self-reporting of pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable).

    Time frame: baseline, 3 and 6 months

  6. Neurological status change

    Change from baseline in motor function (graded 0 - no movement to 4 - active movement against resistance), reflexes (0 - absence to 4 - abnormal/hyperactive) and sensory status (graded normal or abnormal) based on physician's physical exam at 1, 3, and 6 months.

    Time frame: baseline to 6 months

  7. Return to work

    Patient reported return to work - same or different capacity responses to employment questions will be assessed across time points and compared.

    Time frame: baseline - 6 months

  8. Magnetic Resonance Imaging (MRI) review to determine disc health changes

    Magnetic Resonance Imaging (MRI) taken at baseline compared to 6 months reviewing changes in treated disc levels (disc height, volume hydration of disc and Modified Pfirrman grade, T1rho relaxation, T2 relaxation for up to 10 subjects)

    Time frame: baseline-6 months

07

Study locations

6 sites
  • California Orthopedics and Spine
    Larkspur, California 94939, United States
  • Source Health
    Santa Monica, California 90404, United States
  • IPM Medical Group
    Walnut Creek, California 94598, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Clinical Investigations, LLC
    Edmond, Oklahoma 73013, United States
  • Virginia iSpine
    Richmond, Virginia 23235, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jan 2023, 12 months.

Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's 12 months is below that.

Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2021
First posted
Jan 21, 2022
StartActual
Dec 30, 2021
Primary completionActual
Jan 5, 2023
CompletionEst.
Dec 27, 2024
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05201287
Lead sponsor
VIVEX Biologics, Inc.
Collaborators
MCRA
Responsible party
Sponsor
First posted
Jan 21, 2022
Start date
Dec 30, 2021
Primary completion
Jan 5, 2023
Completion
Dec 27, 2024 (estimated)
Last update
Apr 29, 2024

Study contacts

Douglas Beall, MD
principal investigator · Clinical Radiology of Oklahoma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion